



Web: www.AgileIV.com | Tel: (201) 751-2202 | Fax: (201) 266-0437 | Email: info@AgileIV.com

TEPEZZA MEDICATION ORDER

Please complete all attached pages.

- Only the two hub pages should be submitted to Amgen (formerly Horizon Therapeutics) via fax at 833-469-8333.
- All the pages, including the hub pages, should be sent to Agile Infusion, either via the upload portal or via fax at (201) 266-0437.

The forms must be as complete as possible, including a weight-based dose in milligrams. Kindly include a clear copy of the patient's insurance information.

Signatures by the patient and prescriber are required as indicated on the hub forms.

Completing all lines of the worksheet will significantly ease the authorization process. Once the case is transferred to us, we will contact your office to obtain supporting documentation (including lab results and medical records).

Thank you!

PATIENT ENROLLMENT FORM

Submit a completed form by fax 1-833-469-8333 or email TEPEZZAHBYS@horizontherapeutics.com

Initiate the patient enrollment process by completing ALL REQUIRED FIELDS indicated by *. For patient support and/or assistance obtaining patient signature, call Horizon By Your Side at 1-833-5-TEPEZZA (1-833-583-7399).



P-TEP-US-00323-5

PATIENT INFORMATION

First name* Last name* Sex: Male Female

Date of birth*: ____/____/____ (MM/DD/YYYY) Primary language

Primary Phone Number* Home Cell Consent to: Send text message? Yes No Leave voice message? Yes No

Email address

Address*

City* State* Zip code*

Alternate contact name Alternate contact telephone

DIAGNOSIS (Required for benefits investigation.)

Primary diagnosis code* E05.00 — Thyrotoxicosis with diffuse goiter without thyrotoxic crisis or storm (hyperthyroidism)

Additional disease manifestation codes: _____ Date of initial Thyroid Eye Disease (TED) diagnosis: ____/____/____ (MM/YYYY)

Patient's Clinical Activity Score (CAS) [0-10 Range]: _____

INSURANCE INFORMATION

Complete the following OR attach front-back copies of insurance card(s).

Primary Insurance* Secondary Insurance

Policy #* Policy #

Policyholder's first and last name* Policyholder's first and last name

Insurance company telephone* Insurance company telephone

Group #* Group #

Policyholder's DOB*: ____/____/____ (MM/DD/YYYY) Policyholder's DOB: ____/____/____ (MM/DD/YYYY)

IPA/Medical group Name IPA/Medical group Phone Number

Patient is uninsured to my knowledge.

State requirements: The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Noncompliance with state-specific requirements could result in outreach to the prescriber.

PATIENT AUTHORIZATION

Patient signature Date (MM/DD/YYYY)

Please read page 2

Printed full name

Please see Important Safety Information on next page and Full Prescribing Information at TEPEZZAhcp.com.

PRESCRIBER INFORMATION

First name* Last name*

Address*

City* State* Zip code*

NPI #* Tax ID #* State license #*

Clinic/hospital affiliation

Office contact name* Office contact telephone*

Office Contact Email Address* Fax* Telephone

Specialty: _____ Preferred communication: Email

REFERRING PHYSICIAN (Complete if patient was sent to you by another physician. They will be part of the patients care team.)

First and Last Name Specialty

Address

City State Zip code Telephone

PREFERRED INFUSION FACILITY (If none, Horizon By Your Side can provide options.)

Agile Infusion 201-266-0437
Facility name Fax Number

Whichever location is most convenient

Address 201-751-2202
City State Zip code Telephone

Facility NPI # Tax ID #

PRESCRIPTION (Required for specialty pharmacy benefit or home infusion.)

Medication: TEPEZZA® (teprotumumab-trbw) for injection, for intravenous use//500-mg vial

Directions: 1 peripheral IV infusion every 3 weeks for a total of 8 infusions. Administer the first 2 infusions over 90 minutes. Subsequent infusions may be reduced to 60 minutes, if tolerated. Please see Dosing and Administration section of Prescribing Information for additional instruction.

Dose*: Infusion 1: _____ mg (10mg/kg) Infusions 2-8: _____ mg (20mg/kg)
21-day supply; 1 prescription; no refill 21-day supply; 1 prescription; 6 refills

Weight*: _____ lbs kg TEPEZZAdosing.com

Allergies*: _____ or No known drug allergies (NKDA)

Patient is Medically Urgent. I attest the patient is both (1) is experiencing compressive optic neuropathy secondary to Thyroid Eye Disease and (2) requires accelerated treatment with TEPEZZA.

Nursing orders for home infusion: Provide skilled nursing visit to administer medication, provide education, and assess patient (required for home infusion). Saline flushes and other administration supplies authorized as needed.

Fluids for reconstitution/administration: Reconstitute each vial with 10 mL of Sterile Water for Injection, USP. Administer via an infusion bag containing 0.9% Sodium Chloride Injection, USP. For doses <1800 mg, use a 100 mL bag. For doses ≥ 1800 mg, use a 250 mL bag.

PRESCRIBER CERTIFICATION (Required—please see certification language on the next page.)

Prescriber signature/Dispense as written* Date (MM/DD/YYYY)

Substitutions allowed Written or e-signature only; stamps not acceptable.

I certify that the above therapy is medically necessary for the treatment of documented Thyroid Eye Disease (TED)*

The above signature grants permission to share records with the co-management team and infusion facility.

Prescriber Certification

Please read and provide signature in Prescriber Certification section on page 1

I certify that the above therapy is medically necessary, that the information provided is accurate to the best of my knowledge and that my patient is being administered TEPEZZA (teprotumumab-trbw), for intravenous infusion in accordance with the labeled use of the product. I understand that Horizon Therapeutics USA, Inc. and its affiliates and their respective employees or agents (collectively, "Horizon") will use this information to administer the Horizon By Your Side program (the "Program"), which provides a wide array of patient-focused services, including providing logistical and non-medical treatment support for TEPEZZA, as prescribed, and educating about the insurance process. I authorize these parties to act on my behalf for the limited purposes of transmitting this prescription by facsimile to the appropriate pharmacy designated by the patient utilizing their benefit plan. By my signature, I also certify that (1) my patient or his/her personal representative has provided a signed HIPAA authorization that allows me to share protected health information with Horizon for purposes of the Program and (2) I have obtained the patient's authorization to release such information as may be required for AllCare Plus Pharmacy (or another party acting on behalf of Horizon) to assess insurance coverage for TEPEZZA and assistance in initiating or continuing TEPEZZA as prescribed. I further understand and agree that (a) any medication or service provided through the Program as a result of this form is for the named patient only and is not being made in exchange for any express or implied agreement or understanding that I would recommend, prescribe, or use TEPEZZA or any other Horizon product or service, for any other person; (b) my decision to prescribe TEPEZZA was based solely on my professional determination of medical necessity; and (c) I will not seek reimbursement for any medication or service provided by or through the Program from any government program or third-party insurer. I understand that Horizon may modify or terminate the Program at any time without notice. The completion and submission of coverage- or reimbursement-related documentation are the responsibility of the patient and healthcare provider. Horizon makes no representation or guarantee concerning coverage or reimbursement for any item or service. On behalf of the patient, Horizon expects the prescriber to coordinate with Horizon By Your Side to provide, to the best of the prescriber's ability, in-network infusion services and work with Horizon By Your Side to effectively communicate both in-network and out-of-network choices and the corresponding financial obligations of the patient connected to each choice. Should the prescriber knowingly perform out-of-network services without the knowledge and consent of the patient, the prescriber cannot balance bill the patient for the out-of-network services.

State requirements: The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Noncompliance with state-specific requirements could result in outreach to the prescriber.

By filling out and signing this form, the enrollment process in Horizon By Your Side has initiated; however, your patient must sign a Patient Authorization to complete enrollment in Horizon By Your Side. Please note that your patient will not benefit from the services and support offered by the Program unless your patient signs a Patient Authorization, consenting to receiving such services. If your patient does not sign the Patient Authorization contained within this form, Horizon will contact the patient to determine whether the patient is interested in signing a separate Patient Authorization.

Patient Consent for Patient Information, Enrolling in Services, and Accessing Financial Support (referred to as "Patient Authorization")

Please read and provide signature in Patient Authorization section on page 1

I hereby authorize my healthcare providers, my health insurance carriers, and my pharmacies to use and disclose my individually identifiable health information, including my medical records, insurance coverage information, and my name, address, and telephone number to Horizon Therapeutics USA, Inc. and its affiliates and their respective agents and representatives (collectively, "Horizon"), including third parties authorized by Horizon to administer drug support and to dispense drugs (collectively, "Horizon By Your Side") for the following purposes: (1) to establish eligibility for benefits; (2) to communicate with my healthcare providers and me about my treatment or condition and related products; (3) to facilitate the provision of products, supplies, or services by a third party including, but not limited to, specialty pharmacies; (4) to register me in any applicable product registration program required for my treatment; (5) to enroll me in eligible patient support programs offered by Horizon By Your Side and/or Horizon, including nursing or patient access support services (government-reimbursed programs may not be eligible for all support services offered; please contact Horizon By Your Side for determination); and (6) to send me marketing information or offer me products and services related to my treatment or condition (or other products or services in which I might be interested) and to contact me occasionally to obtain my feedback (for market research purposes only) about my treatment, my condition, or my experience with Horizon and/or Horizon By Your Side otherwise as required or permitted by law. Further, I appoint the Program, on my behalf, to proceed with Program services and to convey this prescription to the dispensing pharmacy, to the extent permitted under state law. I understand the pharmacies may receive a fee from Horizon in exchange for (1) providing me with certain materials and information described above, and (2) using or disclosing certain health information pursuant to this Authorization.

I understand that Horizon, as well as my healthcare providers, cannot require me, as a condition of having access to medications, prescription drugs, treatment, or other care, to sign this Authorization. I understand that I am entitled to a copy of this Authorization.

I understand that information disclosed pursuant to this Authorization in some cases may be redisclosed by the recipient and no longer protected by HIPAA or other privacy laws. But Horizon has agreed to use and disclose my information only for purposes of operating the Program. I understand that I may cancel this Authorization at any time by mailing a signed letter requesting such cancellation to Horizon By Your Side, 1 Horizon Way, Deerfield, IL 60015, but that this cancellation will not apply to any information used or disclosed by my healthcare providers and/or health insurance carriers based on this Authorization before they are notified that I have cancelled it. Unless required by state law, this Authorization is valid for whichever is greater: (a) the duration remaining on this treatment or (b) 10 years from the date signed on page 1. A photocopy of this Authorization will be treated in the same manner as the original.

INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with TEPEZZA. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving TEPEZZA.

Hearing Impairment Including Hearing Loss: TEPEZZA may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients' hearing before, during, and after treatment with TEPEZZA and consider the benefit-risk of treatment with patients.

ADVERSE REACTIONS

The most common adverse reactions (incidence \geq 5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, weight decreased, nail disorders, and menstrual disorders.

Please see [Full Prescribing Information](#) or visit TEPEZZAhcp.com for more information.



TEPEZZA and the HORIZON logo are trademarks owned by or licensed to Horizon.
© 2023 Horizon Therapeutics plc P-TEP-US-00323-5 09/23





TEPEZZA AUTHORIZATION INFORMATION WORKSHEET

Patient's Name (Last, First, Middle) _____ DOB _____

Please provide **all** of the following information as possible to enable us to more efficiently obtain insurance authorization for the patient's Tepezza therapy. If you are missing any of this information, please either provide us with the contact information for the patient's other provider(s) who we can contact this information, or take steps for your office staff to arrange for it (such as ordering lab tests). If you have any questions, please do not hesitate to contact us.

Patient's height in feet and inches _____ Patient's weight in pounds _____

Most recent Clinical Activity Score (CAS): _____ Date of this CAS: _____

Patient's Thyroid Eye Disease (TED) is: active inactive

Patient's (TED) grade is: mild moderate moderate-to-severe severe

Please provide information on the patient's TED symptoms:

- Moderate or severe soft-tissue involvement: Yes No
- Diplopia: Yes No
- Lid Retraction: Yes No (If yes, how many mm? _____)
- Exophthalmos / Proptosis: Yes No (If yes, how many mm above normal for race and gender? _____)

Has the patient previously been treated with Tepezza? Yes No (If yes, how many treatments? _____)

Has the patient previously had orbital decompression surgery for their TED? Yes No (If yes, when? _____)

Is the patient's TED condition sight threatening if surgery is not immediately obtained? Yes No

Has the patient previously had orbital radiation for their TED? Yes No (If yes, when? _____)

Does the patient have corneal decompensation that is unresponsive to medical management? Yes No

Please provide information on steroid use for the patient's TED symptoms:

- Has the patient tried steroids but had unsatisfactory results: Yes No
 - If Yes, how were the steroids administered? Orally Intravenously
- Are steroids contraindicated in this patient? Yes No (If yes, why? _____)

Is the patient diabetic? Yes No (If yes, is it under control? Yes No)

Does the patient have any reduction in visual acuity due to optic neuropathy in the past 6 months? Yes No

Is the patient planning to concurrently use any other biological immunomodulator? Yes No
(If yes, which medication(s)? _____)

Attach laboratory blood test results for Free-T3 and Free-T4 levels. Other thyroid laboratory results may be sent, but these two specific tests are required by most carriers. Results should not be more than 90 days old.

Provider Name: _____ Signature: _____ Date: _____